Healio Psoriatic Disease Current Issue
The following articles appeared in the print edition of Healio Psoriatic Disease.
Table of Contents
- Redefining alternative therapies as integrative adds benefits for patients with psoriasis Rebecca L. Forand
-
- Bimekizumab shows long-term efficacy, tolerability in psoriatic arthritis Rob Volansky
- Dermatology atlas launches free online gallery of more than 800 images of 110 conditions
- FDA approves Fresenius Kabi’s Idacio as eighth adalimumab biosimilar Jason Laday
- MedPAC asks Congress to increase physician payments Andrew (Drew) Rhoades
- Orismilast achieves positive results in psoriasis, fast track for hidradenitis suppurativa
- Patients with IMIDs, hybrid immunity may be able to delay fourth COVID-19 vaccine dose Erich Martin
- Risankizumab improves symptoms, is well tolerated in psoriatic arthritis through 52 weeks Erich Martin
- Roflumilast cream significantly reduces itch in chronic plaque psoriasis
-
- Survey results indicate nearly 19 million US adults may have long COVID Caitlyn Stulpin
- Tofacitinib provides sustained dactylitis improvement in psoriatic arthritis Erich Martin
- As interest in alternative medicine grows, patients with psoriasis weigh benefits, risks Joel M. Gelfand, MD, MSCE
- Deucravacitinib superior to placebo, apremilast in plaque psoriasis treatment Gabrielle M. Grasso
- Inflammatory bowel disease may be causal risk for psoriasis, psoriatic arthritis Gabrielle M. Grasso
- Severity of psoriasis increases risk for rare infections, hospital treatment Gabrielle M. Grasso
- Smoking, obesity-related factors significantly increase psoriasis risk Gabrielle M. Grasso
- Q&A: Arcutis educational campaign seeks to reduce emotional toll of psoriasis Hunter Firment
-